Anti-Nausea pill may alter chemo levels in sarcoma patients
NCT ID NCT03514381
First seen Apr 28, 2026 · Last updated Jun 24, 2026 · Updated 12 times
Summary
This study looked at 59 soft tissue sarcoma patients to see if the anti-nausea drug aprepitant changes the amount of the chemotherapy drug ifosfamide in their blood. Patients received ifosfamide and doxorubicin in their first cycle without aprepitant, then added aprepitant in the second cycle. Blood samples were taken to compare ifosfamide levels. The goal was to understand any drug interaction, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Regional Du Cancer de Montpellier (Icm)
Montpellier, 34298, France
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aprepitant (anti-nausea drug) and ifosfamide (chemotherapy)
What this could lead to
If successful, this could help doctors understand whether aprepitant changes how ifosfamide works, potentially leading to safer or more effective chemotherapy regimens for sarcoma patients.
What could go wrong
This is a small, completed Phase 4 study focused on drug interactions, not on curing or treating sarcoma directly. Results may not change clinical practice or apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.